glycotope产品代理
glycotope产品代理
Glycotope 是一家生物技术公司，利用专有技术平台开发独特的肿瘤特异性单克隆抗体。我们结合了糖生物学方面的专业知识和抗体开发方面的专业知识，以推进一流的基于抗体的（免疫）肿瘤学疗法。
技术平台：与健康细胞相比，癌细胞显示出改变的糖基化模式，使这些糖表位成为非常有趣的治疗靶点。我们开发了一种目标发现方法，使我们能够识别在多种适应症的癌组织中表达时携带异常糖基化的蛋白质。
我们的抗体针对特定的肿瘤相关碳水化合物结构或蛋白质/碳水化合物组合糖表位 (GlycoTargets)。基于其卓越的肿瘤特异性，我们的抗体适合以一系列不同的作用模式进行开发，包括裸抗体、双特异性抗体、抗体药物偶联物、细胞疗法或融合蛋白。
Glycotope 成立于柏林。今天，公司有大约 30 名员工在柏林-布赫生物技术园区工作，以进一步发展我们的技术和实现我们的愿景。
EXCEPTIONAL EXPERIENCE IN GLYCOBIOLOGY AND THERAPEUTIC ANTIBODY DEVELOPMENT
Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. We combine expertise in glycobiology and know-how in antibody development to advance first-in-class antibody-based therapeutics for (immuno)-oncology.
Technology Platform: Cancer cells show altered glycosylation patterns compared to healthy cells making these glyco-epitopes highly interesting therapeutic targets. We have developed a target-discovery approach that enables us to identify proteins that carry an aberrant glycosylation if expressed in cancerous tissues of several indications.
Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Based on their superior tumor-specificity, our antibodies are suitable for development in an array of different modes of action including naked antibodies,
bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins.
Glycotope was founded in Berlin. Today, the Company has ~30 employees working on the Berlin-Buch Biotech Campus on the further development of our technology and the realization of our vision.
